The Gummy Project

Potent Ventures Establishes New Partnership with New York Based "The Bee Conservancy" to Enact Its Purpose-Driven Keystone Species Strategy for the Gummy Project

Potent Ventures Inc. (CSE: POT) (FSE: 0OS2) (OTCQB: POTVF) ("Potent" or the "Company") is excited to announce that it has established a partnership with "The Bee Conservancy," forming the foundation for its purpose-driven endangered Keystone Species product marketing strategy for The Gummy Project's initial gummy product line, featuring Bees and Sharks.

  • The Bee Conservancy partnership paves way for the launch of The Gummy Project purpose driven strategy, delivering consumer reach, educational content and co-marketing across multiple communications channels
  • The Gummy Project to Champion endangered Keystone Species, supporting global efforts to raise awareness and protect endangered Keystone Species through the sale of high-quality gummy products and engaging storytelling
  • Bee and Shark Gummies to lead the way for consumer launch and building purpose driven conservation partnerships

"Our new partnership with "The Bee Conservancy" is fundamental to the The Gummy Project's commitment to helping raise awareness of endangered species that are crucial to the world's ecosystems," said Mr. Charlie Lamb, CEO of the Company. "We will be working collaboratively with the Bee Conservancy to align our Keystone Species strategy across multiple channels including, packaging, education, media promotion, social influencers, events and more as we support their efforts to protect bees, which are critical to all life on this planet."

The Bee Conservancy / Gummy Project Partnership Highlights

  • Gummy Project's purpose-driven mandate aligns strongly with The Bee Conservancy's mission to "protect bees and the environments that sustain them to ensure ecological health and security for all"
  • The purpose of this partnership is to "protect bees, safeguard the environment, and secure food justice through community-based education, research, habitat creation and advocacy," through the engagement of consumers with The Gummy Project's innovative Keystone Species strategy
  • The Honeybee Conservancy was founded in 2009 by Guillermo Fernandez in direct response to a tremendous decline in bee populations globally
  • The Bee Conservancy's initiatives, such as their flagship program Sponsor-a-Hive, have served hundreds of thousands of people across the United States, and protected an estimated 10 million bees to date
  • The Gummy Project will donate 8% of the net proceeds the sale of its Bee shaped gummy products from 1 March 2022 to 28 February 2023

"The Bee Conservancy is extremely grateful for the support of The Gummy Project," says Rebecca Louie, Executive Director of the Bee Conservancy. "Their donation will help advance our mission to protect bees and bee habitats. This is a compelling opportunity to connect communities directly with the importance of these precious pollinators, and we are excited to align with a company committed to raising awareness and support for bees and ecosystems everywhere."

The Gummy Project's initial launch will feature two endangered Keystone Species, Sharks and Bees. Long term, The Gummy Project aspires to develop a robust endangered Keystone Species product mix, connecting with consumers through content, merchandise and live experiences that support conservation efforts with these endangered species and their ecosystems.

About Keystone Species1

"A keystone species-which can be any organism, from animals and plants to bacteria and fungi-is the glue that holds a habitat together. It may not be the largest or most plentiful species in an ecological community, but if a keystone is removed, it sets off a chain of events that turns the structure and biodiversity of its habitat into something very different. Although all of an ecosystem's many components are intricately linked, these are the living things that play a pivotal role in how their ecosystem functions.

Keystone species maintain the local biodiversity of an ecosystem, influencing the abundance and type of other species in a habitat. They are nearly always a critical component of the local food web. One of the defining characteristics of a keystone species is that it fills a critical ecological role that no other species can. Without its keystone species, an entire ecosystem would radically change-or cease to exist altogether. It's important to note that a species' role can change from one ecosystem to the next, and a species that is considered a keystone in one environment may not be considered the same in another."

1https://www.nrdc.org/stories/keystone-species-101#whatis

Charlie Lamb, President & CEO, Director
Telephone: 1(236) 317-2812 - Toll free 1(888) 556-9656
E-mail: investors@potent-ventures.com

Neither the Canadian Securities Exchange nor its Regulation Services Provider (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this release.

Forward-Looking Statements
Certain information set forth in this news release may contain forward-looking statements that involve substantial known and unknown risks and uncertainties. All statements other than statements of historical fact are forward-looking statements, including, without limitation, statements regarding the change of business and regulatory and shareholder approval of same, growth of the low sugar and plant-based gummy market, business strategy, corporate vision, proposed expansion, partnerships, joint-ventures and strategic alliances and co-operations, budgets, cost and plans and objectives of or involving the Company. Such forward-looking information reflects management's current beliefs and is based on information currently available to management. Often, but not always, forward-looking statements can be identified by the use of words such as "plans", "expects", "is expected", "budget", "scheduled", "estimates", "forecasts", "predicts", "intends", "targets", "aims", "anticipates", "may" or "believes" or variations (including negative variations) of such words and phrases or may be identified by statements to the effect that certain actions "may", "could", "should", "would", "might" or "will" be taken, occur or be achieved. A number of known and unknown risks, uncertainties and other factors may cause the actual results or performance to materially differ from any future results or performance expressed or implied by the forward-looking information. These forward-looking statements are subject to numerous risks and uncertainties, certain of which are beyond the control of the Company including, but not limited to, the impact of general economic conditions, industry conditions, risks relating to epidemics or pandemics such as COVID-19, including the impact of COVID-19 on the Company's business, financial condition, and results of operations. Readers are cautioned that the assumptions used in the preparation of such information, although considered reasonable at the time of preparation, may prove to be imprecise and, as such, undue reliance should not be placed on forward-looking statements. The Company does not assume any obligation to update or revise its forward-looking statements, whether as a result of new information, future events, or otherwise, except as required by securities laws.

Click here to connect with Potent Ventures Inc. (CSE: POT) (FSE: 0OS2) (OTCQB: POTVF) to receive an Investor Presentation

Source

The Conversation (0)
Genes and chromosomes with "2024" overlay.

Biotech Market Update: Q1 2024 in Review

The first quarter of 2024 witnessed a surge in initial public offerings (IPOs) and mergers and acquisitions (M&A) within the biotech industry, signaling continued interest from investors.

AstraZeneca’s acquisition of start-up Amolyt on March 14, and its longtime biotech partner Fusion Pharmaceuticals for US$2.4 billion on March 19 marked the third acquisition of a radiopharmaceutical developer in recent months. As of writing, there have been 14 M&A deals struck in 2024, according to data from Biopharma Dive.

Investment bank Jefferies released data in early March revealing that the sector was on track to earn its highest quarterly total in three years, reflecting the cautiously optimistic outlook at this year's JPM24 conference.

Keep reading...Show less

AMGEN TO PRESENT TEZSPIRE® PHASE 2A COPD DATA AT ATS 2024

Planning Underway for Phase 3 Development of Tezepelumab in COPD

Amgen (NASDAQ:AMGN) today provided an update regarding the results of the Phase 2a COURSE trial for TEZSPIRE ® (tezepelumab-ekko) in chronic obstructive pulmonary disease (COPD), which were accepted for presentation in the Clinical Trials Symposium at The American Thoracic Society (ATS) 2024 International Conference on Monday, May 20 from 9:15-11:15 a.m. PDT .

News Provided by PR Newswire via QuoteMedia

Keep reading...Show less
Close up 3D rendering of DNA strands.

Biotech Stocks: 5 Biggest Companies in 2024

What are the top biotech companies? The following five stocks have market capitalizations worth billions of dollars and operate in countries all around the globe.

Plus, these big-name biotech players have pipelines stuffed with potentially disruptive products — and enough revenue to recover should some of those products fail.

This means that investors can experience the excitement of biotech investing while minimizing risk. Although returns are never guaranteed, company size can insulate investors from volatility.

Keep reading...Show less
SIRONA BIOCHEM Corporate Update April 2024

SIRONA BIOCHEM Corporate Update April 2024

Sirona Biochem Corp . (TSX-V: SBM) (FSE: ZSB) (OTC: SRBCF) (" Sirona " or the " Company ") provides the following update:

Dear shareholders,

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less
Sirona Biochem Announces Close of Private Placement

Sirona Biochem Announces Close of Private Placement

Vancouver, British Columbia – April 4, 2024 Sirona Biochem Corp . (TSX-V: SBM) (Frankfurt: ZSB) (" Sirona ") has closed its private placement (Private Placement") for gross proceeds of $132,500 CAD. The Private Placement consists of 1,325,000 units, (the "Units") at a price of $0.10 per Unit. Each Unit consists of one common share and one transferable share purchase warrant, each whole warrant exercisable into one additional common share of the Company for a period of 2 years from the date of issue at a price of $0.15 per Share in year one and $0.25 per Share in year two. All securities issued under the Private Placement are subject to statutory hold periods expiring on August 4, 2024.

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less
Need injecting into red and white cell.

How to Invest in Biotechnology (Updated 2024)

Investors interested in the life science sector are well aware of the importance of biotechnology.

From finding cures for diseases to feeding future generations, many areas of day-to-day life are influenced by players in the biotechnology space, and expert projections show the industry's future looks bright.

But how can investors gain exposure to biotechnology? Here’s a brief overview of how to invest in the expanding biotechnology market, from stocks to watch to exchange-traded funds (ETFs).

Keep reading...Show less

Latest Press Releases

Related News

×